This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lutz, J. E.
Right arrow Articles by Stevens, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lutz, J. E.
Right arrow Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Jul 1997, 1558-1561, Vol 41, No. 7
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

JE Lutz, KV Clemons, BH Aristizabal and DA Stevens
Department of Medicine, Santa Clara Valley Medical Center, and California Institute for Medical Research, San Jose 95128, USA.

SCH 56592 (SCH) is a new triazole antifungal with a broad spectrum of activity. In vitro susceptibility testing against five strains of Coccidioides immitis revealed MICs from 0.39 to 3.13 microg/ml and minimal fungicidal concentrations from 1.56 to 3.13 microg/ml. A murine model of systemic coccidioidomycosis was established in female CD-1 mice. Groups received either no treatment or oral therapy with fluconazole at 10 or 100 mg/kg of body weight; itraconazole at 10 or 100 mg/kg; SCH at 0.5, 2, 10, or 25 mg/kg; or its methylcellulose diluent alone. Therapy began 2 days postinfection and continued once daily for 19 days. Surviving mice were euthanized 49 days postinfection, and infectious burdens were determined by culture. All drugs were superior to no-treatment or diluent-treatment controls (P < 0.001) in prolonging survival but were not significantly different from one another. Itraconazole at 100 mg/kg was superior to fluconazole in reduction of CFU in the spleen, liver, and lung (P < 0.01 to 0.001). SCH at 0.5 mg/kg was superior to either fluconazole or itraconazole at 10 mg/kg in reduction of CFU in all three organs (P < 0.05 to 0.001). SCH at 2 mg/kg was not significantly different from itraconazole at 100 mg/kg in all three organs. SCH at 10 and 25 mg/kg was superior to either dose of fluconazole or itraconazole in all three organs (P < 0.05 to 0.001). In terms of reduction of CFU, SCH was > or = 200-fold as potent as fluconazole and > or = 50-fold as potent as itraconazole. There was a clear dose-responsive relationship for SCH in each of the organs. It is noteworthy that SCH effected cures (no detectable C. immitis in any organ) in 1 of 9, 6 of 10, or 9 of 9 surviving mice in animals given 2, 10, or 25 mg/kg, respectively. Neither fluconazole nor itraconazole cured any survivor. SCH has potent, fungicidal activity in vivo against C. immitis. It should be considered for clinical trials in patients with coccidioidomycosis.


This article has been cited by other articles:

  • Stevens, D. A., Rendon, A., Gaona-Flores, V., Catanzaro, A., Anstead, G. M., Pedicone, L., Graybill, J. R. (2007). Posaconazole Therapy for Chronic Refractory Coccidioidomycosis. Chest 132: 952-958 [Abstract] [Full Text]  
  • Kamberi, P., Sobel, R. A., Clemons, K. V., Waldvogel, A., Striebel, J. M., Williams, P. L., Stevens, D. A. (2007). Comparison of Itraconazole and Fluconazole Treatments in a Murine Model of Coccidioidal Meningitis. Antimicrob. Agents Chemother. 51: 998-1003 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E. (2004). Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48: 3801-3805 [Abstract] [Full Text]  
  • Hsue, G., Napier, J. T., Prince, R. A., Chi, J., Hospenthal, D. R. (2004). Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 54: 292-294 [Full Text]  
  • Danaher, P. J., Cao, M. K., Anstead, G. M., Dolan, M. J., DeWitt, C. C. (2004). Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 53: 115-117 [Abstract] [Full Text]  
  • Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., Verweij, P. E. (2003). Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrob. Agents Chemother. 47: 3647-3650 [Abstract] [Full Text]  
  • Graybill, J. R., Najvar, L. K., Gonzalez, G. M., Hernandez, S., Bocanegra, R. (2003). Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 51: 1373-1376 [Abstract] [Full Text]  
  • Sun, Q. N., Najvar, L. K., Bocanegra, R., Loebenberg, D., Graybill, J. R. (2002). In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model. Antimicrob. Agents Chemother. 46: 2310-2312 [Abstract] [Full Text]  
  • Gonzalez, G. M., Tijerina, R., Najvar, L. K., Bocanegra, R., Rinaldi, M., Loebenberg, D., Graybill, J. R. (2002). In Vitro and In Vivo Activities of Posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother. 46: 1352-1356 [Abstract] [Full Text]  
  • Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., Graybill, J. R. (2002). In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes. Antimicrob. Agents Chemother. 46: 1581-1582 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Najvar, L. K., Bocanegra, R., Caselli, F., Di Cesare, S., Giannini, D., Di Francesco, L. F., Giacometti, A., Carle, F., Scalise, G., Graybill, J. R. (2001). Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 1355-1359 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Galgiani, J. N., Catanzaro, A., Cloud, G. A., Johnson, R. H., Williams, P. L., Mirels, L. F., Nassar, F., Lutz, J. E., Stevens, D. A., Sharkey, P. K., Singh, V. R., Larsen, R. A., Delgado, K. L., Flanigan, C., Rinaldi, M. G. (2000). Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis: A Randomized, Double-Blind Trial. ANN INTERN MED 133: 676-686 [Abstract] [Full Text]  
  • Manavathu, E. K., Cutright, J. L., Loebenberg, D., Chandrasekar, P. H. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: 229-234 [Abstract] [Full Text]  
  • Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
  • Sorensen, K. N., Sobel, R. A., Clemons, K. V., Pappagianis, D., Stevens, D. A., Williams, P. L. (2000). Comparison of Fluconazole and Itraconazole in a Rabbit Model of Coccidioidal Meningitis. Antimicrob. Agents Chemother. 44: 1512-1517 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Nomeir, A. A., Kumari, P., Hilbert, M. J., Gupta, S., Loebenberg, D., Cacciapuoti, A., Hare, R., Miller, G. H., Lin, C.-C., Cayen, M. N. (2000). Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys. Antimicrob. Agents Chemother. 44: 727-731 [Abstract] [Full Text]  
  • Molina, J., Martins-Filho, O., Brener, Z., Romanha, A. J., Loebenberg, D., Urbina, J. A. (2000). Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob. Agents Chemother. 44: 150-155 [Abstract] [Full Text]  
  • Barchiesi, F., Arzeni, D., Fothergill, A. W., Di Francesco, L. F., Caselli, F., Rinaldi, M. G., Scalise, G. (2000). In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens. Antimicrob. Agents Chemother. 44: 226-229 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Loebenberg, D., Rex, J. H. (1999). Treatment of Murine Fusariosis with SCH 56592. Antimicrob. Agents Chemother. 43: 589-591 [Abstract] [Full Text]  
  • Galgiani, J. N. (1999). Coccidioidomycosis: A Regional Disease of National Importance: Rethinking Approaches for Control. ANN INTERN MED 130: 293-300 [Abstract] [Full Text]  
  • Connolly, P., Wheat, J., Schnizlein-Bick, C., Durkin, M., Kohler, S., Smedema, M., Goldberg, J., Brizendine, E., Loebenberg, D. (1999). Comparison of a New Triazole Antifungal Agent, Schering 56592, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice. Antimicrob. Agents Chemother. 43: 322-328 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (1998). Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts. J. Clin. Microbiol. 36: 2950-2956 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»